- Michotte A, Veld P, Chaskis C, Sciot R, Menten J, Joossens EJ, Strauven T, D’Hondt LA, Sartenaer D, Califice SF, Bierau K, Svensson C, De Grève J, Neyns B. MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma. Eur J Cancer., 45(1):146-53 (2009).
- Fontaine C, Meulemans A, Huizing M, Collen C, Kaufman L, De Mey J, Bourgain C, Verfaillie G, Lamote J, Sacre R, Schallier D, Neyns B, Vermorken J, De Grève J. Breast. Tolerance of adjuvant letrozole outside of clinical trials. Breast,17(4):376-81 (2008).
- Vermeij J, Teugels E, Bourgain C, Xiangming J, in ‘t Veld P, Ghislain V, Neyns B, De Grève J. Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers.BMC Cancer, 8;8:3 (2008).
- Decoster L, Schallier D, Everaert H, Nieboer K, Meysman M, Neyns B, De Mey J, De Grève J. Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC). Lung Cancer, 62(1):55-61 (2008)
- Neyns B, Van Nieuwenhove Y, Aerts M, Fontaine C, Vermeij J, Schallier D, Decoster L, De Mey J, Vandenbroucke F, Hoorens A, Delvaux G, De Gréve J. Hepatic arterial infusion of oxaliplatin and L-folinic acid-modulated 5-fluorouracil for colorectal cancer liver metastases. Anticancer Res, 26(1B):611-9 (2006).
Reviews
- De Grève J, Sermijn E, De Brakeleer S, Ren Z, Teugels E. Hereditary breast cancer: from bench to bedside. Curr Opin Oncol. 2008 Nov;20(6):605-13. Review.
- De Grève J, Decoster L, Van Meerbeek J, Vermeij J, Teugels E, Schallier D. Targeted therapies in the treatment of non-small cell lung cancer. Bull Cancer. 95(3):358-64 (2008).
- De Grève J, Schallier D, De Coster L, Declercq I, Vermeij J, Vansteenkiste J, Van Meerbeek J. Integration of targeted therapies in the treatment of advanced non-small cell lung cancer. BJMO,1:30-9 (2007)
- De Grève J. Enriching for sensitive patient populations with targeted agents: not only an issue of cost but also of safety. BJMO,2:176-8 (2008).
- Sermijn E, Teugels E, Bonduelle M, De Grève J. Clinical aspects of hereditary breast and ovarian cancer. BJMO 2:198-204 (2008).
- Decoster L, Schallier D, De Grève J. First-line treatment algorithm for advanced non-small cell lung cancer in 2010: integration of chemotherapy and targeted therapies. BJMO, 4:124-9 (2010).
- Verhoeven D, Van Hoof E, Leto C, Van den Bogaert S, Leysen L, De Grève J. The Belgian Cancer Plan. BJMO, 4:264-7.